NCI Awards HMO Group $16 Million for Cancer Studies

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 9
Volume 8
Issue 9

BETHESDA, Md-The National Cancer Institute will provide $16 million over 4 years to the HMO Research Network to expand and strengthen its cancer research efforts and to initiate studies aimed at increasing effective cancer prevention and control among enrollees in health maintenance organizations.

BETHESDA, Md—The National Cancer Institute will provide $16 million over 4 years to the HMO Research Network to expand and strengthen its cancer research efforts and to initiate studies aimed at increasing effective cancer prevention and control among enrollees in health maintenance organizations.

The HMO Research Network, created in 1996, coordinates research activities among HMO-based researchers. Ten nonprofit managed care organizations that are members of the HMO network will participate in the program, which is known as the Cancer Research Network.

Three specific projects are planned: a study of the effectiveness of HMO smoking cessation activities; an examination of late-stage breast and cervical cancers to uncover factors, such as screening, that could help prevent advanced disease; and an efficacy study of prevention strategies, such as mammography and prophylactic mastectomy, in women with a personal or family history of breast cancer.

Participating organizations are Group Health Cooperative (Seattle); the Meyers Primary Care Institute (Worcester, Mass), a part of Fallon Healthcare System; Harvard-Pilgrim Health Care (Boston); HealthPartners Research Foundation (Minneapolis); Henry Ford Health System/Health Alliance Plan (Detroit); and five Kaiser Permanente divisions, Hawaii (Honolulu), Northern California (Oakland), Northwest (Portland, Ore), Rocky Mountain (Denver), and Southern California (Pasadena).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content